Overview
medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca
AI+ Ask Fintel’s AI assistant about Medicenna Therapeutics Corp..
Thinking about good questions…
Basic Stats
The share price of Medicenna Therapeutics Corp. as of June 11, 2024 is $1.85 / share. The market cap (or net worth) of Medicenna Therapeutics Corp. as of September 8, 2025 is $154.25 MM.
The Factor Analysis chart (below right) shows a view of Medicenna Therapeutics Corp. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 154.25 MM |
| EV | |
| Shares Out. | 83.38 MM |
| Earnings Date | |
| EPS (TTM) | -0.16 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 19.49 |
| Short Shares Avail. | 0.65 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.10 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.34 |
| ROE | -0.57 |
| ROIC | -0.88 |
| CROIC | -1.02 |
| OCROIC | -1.20 |
| Implied Volatility | |
| Put/Call OI Ratio |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Medicenna Therapeutics Corp. is $2.63. The forecasts range from a low of $2.49 to a high of $2.82. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Medicenna Therapeutics Corp.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-11-15 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-11-14 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-11-14 | JONES TRADING | Buy | Buy | Maintains |
| 2023-11-14 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2023-11-06 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2023-10-27 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2023-08-14 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2023-08-13 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2023-08-10 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-08-09 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-08-09 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-08-09 | JONES TRADING | Buy | Buy | Maintains |
| 2023-08-09 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2023-08-08 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-08-08 | JONES TRADING | Buy | Buy | Maintains |
| 2023-08-08 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2023-03-31 | JONES TRADING | Buy | Buy | Maintains |
| 2023-03-30 | JONES TRADING | Buy | Buy | Maintains |
| 2023-03-30 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2023-03-29 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2023-02-08 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-02-07 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-02-07 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-02-07 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2023-02-06 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-02-06 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2022-11-29 | Guggenheim Securities | Buy | Maintains | |
| 2022-11-04 | MAXIM GROUP | Buy | Buy | Maintains |
| 2022-11-03 | MAXIM GROUP | Buy | Buy | Maintains |
| 2022-09-29 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2022-09-29 | STA Research | Speculative Buy | Maintains | |
| 2022-09-28 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2022-08-10 | STA Research | Speculative Buy | Reiterate | |
| 2022-08-10 | Oppenheimer Holdings | Buy | Initiate | |
| 2022-07-28 | Bloom Burton | Buy | Maintains | |
| 2022-07-27 | BROOKLINE CAPITAL MARKETS | Buy | Buy | Maintains |
| 2022-07-26 | BROOKLINE CAPITAL MARKETS | Buy | Buy | Maintains |
| 2022-06-23 | HC Wainwright | Buy | Reiterate | |
| 2022-06-23 | STA Research | Speculative Buy | Maintains | |
| 2022-03-15 | Maxium Group | Buy | Initiate | |
| 2021-09-22 | Bloom Burton | Buy | Initiate | |
| 2020-12-18 | Oppenheimer | Outperform | Initiate | |
| 2020-12-17 | Oppenheimer | Outperform | Initiate | |
| 2020-09-10 | HC Wainwright & Co. | Buy | Initiate | |
| 2019-11-19 | Brookline Capital | Buy | Initiate | |
| 2024-08-01 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2024-07-31 | JONES TRADING | Buy | Buy | Maintains |
| 2024-07-31 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2024-04-09 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2023-11-14 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2023-11-13 | GUGGENHEIM SECURITIES LLC | Buy | Buy | Maintains |
| 2023-11-13 | JONES TRADING | Buy | Buy | Maintains |
| 2023-11-13 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2023-11-05 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2023-10-26 | OPPENHEIMER & CO., INC. | Outperform | Outperform | Maintains |
| 2025-02-12 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2024-12-05 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
| 2024-12-04 | JONES TRADING | Buy | Buy | Maintains |
| 2024-12-04 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2024-12-04 | BLOOM BURTON & CO. | Buy | Buy | Maintains |
| 2025-06-25 | RESEARCH CAPITAL CORPORATION | Buy | Buy | Maintains |
| 2025-04-28 | H.C. WAINWRIGHT & CO., LLC | Buy | Buy | Maintains |
